Bill > HR2554

This bill aims to modify how prescription drug inflation rebates are calculated and applied, focusing on both Medicare Part B and Part D drugs. Specifically, the legislation changes the base year for rebate calculations from 2021 to 2016 and expands the scope of drug units subject to rebates. For Part B drugs, the bill alters how billing units are determined by excluding units paid through state Medicaid plans and adjusting calculation methodologies. For Part D drugs, the bill introduces new exclusions for units covered by Medicaid, units already subject to rebates, and starting in 2026, units covered under the 340B drug pricing program (a federal program that requires drug manufacturers to provide discounts to certain healthcare organizations). The changes would take effect in January 2026 for Part B drugs and October 2025 for Part D drugs. The overall goal appears to be creating a more comprehensive and accurate system for calculating drug pricing and rebates across different healthcare markets, potentially helping to lower prescription drug costs for patients and healthcare systems.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/2554/all-info